The emergence of a large number of antimicrobialresistant organisms is a cause for concern. Nature is historically the source of drugs; indeed a considerable number of drugs have been developed from microorganisms, and are now used daily in the treatment of infectious diseases. However, the introduction to the pharmaceutical market of new therapeutic molecules has decreased during the last two decades. In this review, the genus Micromonospora is proposed as a biofactory for production of new antibiotics. The genus Micromonospora has been investigated extensively and more than 100 antibiotics have been isolated from diverse Micromonospora strains. In addition, recent developments in analytical, biological and bioinformatics screening tools used in the discovery of new therapeutic compounds are described. It may be possible to revive formerly used antibiotics produced by Micromonospora and study of this genus may facilitate discovery of novel bioactive molecules.
A Gram-positive strain, ADR1, was isolated from soil collected from the Algerian Sahara Desert. The ethyl acetate extract of the fermentation broth showed cytotoxic activity against the PANC-1 cell line (37.1 ± 1.3% viability when applied at a concentration of 100 µg/mL). Fractionation and NMR analysis of two peaks absorbing at 490 nm revealed that they represented β- and γ-rubromycin, anticancer antibiotic compounds. The ADR1 strain contained LL-diaminopimelic acid in the whole-cell hydrolysate, and the partial 16S ribosomal RNA gene sequence (1392 bp, Accession No. KF947515) showed 99% sequence similarity to Streptomyces species. Therefore, the name Streptomyces sp. ADR1 was proposed and deposited in the Wellness Industries Culture Collection (WICC) of the Institute of Bioproduct Development, UTM, Malaysia, under the number (WICC- B86). In a 16 L stirred-tank bioreactor, the stain was adapted to submerged culture conditions and produced rubromycins at a relatively high concentration, with maximums of 24.58 mg/L and 356 mg/L for β- and γ-rubromycins, respectively.
In recent years, the study of extracellular vesicles (EVs) has gained increasing attention due to their pivotal role in intercellular communication and their potential as noninvasive biomarkers and innovative therapeutic tools. Their molecular cargo, shaped by the source cell and its microenvironment, offers an accurate mirror of cellular states and pathophysiological dynamics. Characterizing this content provides critical insights into disease mechanisms, while paving the way for novel diagnostic, prognostic and therapeutic strategies. Among their components, proteins and metabolites stand out for their functional relevance and biomarker potential. In this context, proteomics and metabolomics have emerged as key approaches to unravel the molecular complexity of EVs and clarify their biological functions, thereby advancing their translation into clinical applications. This review highlights the contributions of these disciplines, outlines associated analytical workflows, and discusses major technical challenges. A systematic literature search was conducted in PubMed, Web of Science, Scopus, and Google Scholar for studies published between 2012 and 2025, focusing on proteomic and metabolomic analyses of EVs. Emphasis is placed on the need for methodological consensus to standardize protocols, improve inter-laboratory reproducibility, and support the successful clinical application of EV-based strategies.
Pistacia lentiscus L. plays an integral role in Algerian traditional therapy. The aim of this study was to evaluate P. lentiscus methanol extract (PLME) for its potential antihypoxic and antioxidant activity and to characterize its phytochemical profile. Locomotor and exploratory behavior were investigated using the open‐field test (OF). Also, biological activity prediction was performed using the PASS online platform, and molecular docking studies were carried out using AutoDock Vina software. Quantitative investigations revealed high levels of total phenolics (713.952 ± 12.58 mg GAE/g extract) and flavonoids (315.821 ± 2.219 mg QE/g extract). The HPLC‐MS analysis identified phenolic acids and flavonoids. The extract exhibited a dose‐dependent increase in scavenging activity and reducing power. PLME could dose‐dependently enhance the survival time of mice under normobaric hypoxia and after injection of sodium nitrite. PLME significantly decreased the malondialdehyde (MDA) level compared to the control group. Furthermore, PLME increased the number of squares crossed and the number of rearings in the OF test. PLME constituents exhibited favorable binding affinities with the HIF‐1α and drug‐likeness properties. This is the first study to evaluate the antihypoxic efficacy of P. lentiscus L. extract and highlight its significance as a medicinal plant by in vivo and in silico approaches.